Vaccines based on whole recombinant Saccharomyces cerevisiae cells

FEMS Yeast Research

Volumn 10, Issue 8, 2010, Pages 1060-1069

  Ardiani, Andressa ^a   Higgins, Jack P ^a   Hodge, James W ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Antitumor activity; Carcinoembryonic antigen; Immunotherapy; Saccharomyces cerevisiae; Therapeutic vaccine; Yeast vaccine

Indexed keywords

CANCER VACCINE; CARCINOEMBRYONIC ANTIGEN; CISPLATIN; GEMCITABINE; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; NAVELBINE; RAS PROTEIN; SACCHAROMYCES CEREVISIAE VACCINE; UNCLASSIFIED DRUG; VACCINIA ONCOLYSATE; VIRUS VACCINE;

ANTIGEN EXPRESSION; ANTIGEN PRESENTATION; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CLINICAL TRIAL; CROSS PRESENTATION; CYTOKINE PRODUCTION; CYTOTOXICITY; DENDRITIC CELL; FUNGAL CELL; HEPATITIS C; HUMAN; HUMORAL IMMUNITY; IMMUNOSTIMULATION; IMMUNOTHERAPY; LUNG NON SMALL CELL CANCER; LYMPHOCYTE PROLIFERATION; MULTIPLE CYCLE TREATMENT; NONHUMAN; PANCREAS CANCER; PROSTATE CANCER; REVIEW; SACCHAROMYCES CEREVISIAE; T LYMPHOCYTE ACTIVATION; VECTOR CONTROL; VIRUS LOAD;

ANTIGENS, NEOPLASM; ANTIGENS, VIRAL; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; DRUG CARRIERS; FUNGAL VACCINES; GENETIC VECTORS; HUMANS; RECOMBINANT PROTEINS; SACCHAROMYCES CEREVISIAE; VACCINES, SYNTHETIC;

SACCHAROMYCES CEREVISIAE;

EID: 78349275692     PISSN: 15671356     EISSN: 15671364     Source Type: Journal    
DOI: 10.1111/j.1567-1364.2010.00665.x     Document Type: Review

References (50)

1. Arlen PM, Madan RA, Hodge JW, Schlom J & Gulley JL (2007) Combining vaccines with conventional therapies for cancer. Update Cancer Ther 2: 33-39.
2. Barron M, Blyveis N, Pan S & Wilson C (2006) Human dendritic cell interactions with whole recombinant yeast: implications for HIV-1 vaccine development. J Clin Immunol 26: 251-264.
3. Bernstein MB, Chakraborty M, Wansley EK, Guo Z, Franzusoff A, Mostbock S, Sabzevari H, Schlom J & Hodge JW (2008) Recombinant Saccharomyces cerevisiae (yeast-CEA) as a potent activator of murine dendritic cells. Vaccine 26: 509-521.
4. Boehm A, Higgins J, Franzusoff A, Schlom J & Hodge J (2010) Concurrent vaccination with two distinct vaccine platforms targeting the same antigen generates phenotypically and functionally distinct T-cell populations. Cancer Immunol Immun 59: 397-408.
5. Bos JL (1989) ras oncogenes in human cancer: a review. Cancer Res 49: 4682-4689.
6. Britton A, Oakes S, Guo Z, Lu Y, Speyer S, King T, Franzusoff A & Apelian D (2009) Prospective use of an optimized ras mutation diagnostic in an adjuvant phase 2 trial of mutation specific ras-targeted immunotherapy (GI-4000) in pancreas cancer [abstract]. American Association for Cancer Research Annual Meeting, Denver, CO: A9309.
7. Burke KP & Cox AL (2010) Hepatitis C virus evasion of adaptive immune responses: a model for viral persistence. Immunol Res 47: 216-227.
8. Chakraborty M, Gelbard A, Carrasquillo JA, Yu S, Mamede M, Paik CH, Camphausen K, Schlom J & Hodge JW (2008a) Use of radiolabeled monoclonal antibody to enhance vaccine-mediated antitumor effects. Cancer Immunol Immun 57: 1173-1183.
9. Chakraborty M, Wansley EK, Carrasquillo JA et al. (2008b) The use of chelated radionuclide (samarium-153-ethylenediaminetetramethylenephosphonate) to modulate phenotype of tumor cells and enhance T cell-mediated killing. Clin Cancer Res 14: 4241-4249.
10. Clarke P, Mann J, Simpson JF, Rickard-Dickson K & Primus FJ (1998) Mice transgenic for human carcinoembryonic antigen as a model for immunotherapy. Cancer Res 58: 1469-1477.
11. Emens LA & Jaffee EM (2005) Leveraging the activity of tumor vaccines with cytotoxic chemotherapy. Cancer Res 65: 8059-8064.
12. Ferrara TA, Hodge JW & Gulley JL (2009) Combining radiation and immunotherapy for synergistic antitumor therapy. Curr Opin Mol Ther 11: 37-42.
13. Forde KA & Reddy KR (2009) Hepatitis C virus infection and immunomodulatory therapies. Clin Liver Dis 13: 391-401.
14. Forkert PG, Parkinson A, Thaete LG & Malkinson AM (1992) Resistance of murine lung tumors to xenobiotic-induced cytotoxicity. Cancer Res 52: 6797-6803.
15. Franzusoff A, Duke RC, King TH, Lu Y & Rodell TC (2005) Yeasts encoding tumour antigens in cancer immunotherapy. Expert Opin Biol Th 5: 565-575.
16. Galao R, Scheller N, Alves-Rodrigues I, Breinig T, Meyerhans A & Diez J (2007) Saccharomyces cerevisiae: a versatile eukaryotic system in virology. Microb Cell Fact 6: 32.
17. Gameiro S, Caballero J, Boehm A, Higgins J, Franzusoff A, Schlom J & Hodge JW (2008) Chemotherapy can enhance the therapeutic potential for vaccine-mediated immunotherapy [abstract]. American Association for Cancer Research Annual Meeting, Denver, CO.
18. Gold P & Freedman SO (1965) Demonstration of tumor-specific antigens in human colon carcinoma by immunologic tolerance and absorption techniques. J Exp Med 121: 439-462.
19. Gulley JL, Arlen PM, Hodge J & Schlom J (2009) Vaccines and immunostimulants. Holland-Frei Cancer Medicine, 8th edn (Kufe DW, Frei E III, Holland JF, Weichselbaum RR, Pollock RE, Bast RC Jr, Hong WK & Hait WN, eds), pp. 786-801. B.C. Decker, Philadelphia, PA.
20. Haller A, King T, Lu Y, Kemmler C, Gordon G, Bellgrau D, Franzusoff A, Rodell T & Duke R (2005) Whole recombinant yeast-based immunotherapy for treatment of chronic hepatitis C infection induces dose-dependent T cell responses and therapeutic effects without vector neutralization [abstract 132]. Hepatology 42 (Suppl S1): 249A.
21. Heintel T, Breinig F, Schmitt MJ & Meyerhans A (2003) Extensive MHC class I-restricted CD8 T lymphocyte responses against various yeast genera in humans. FEMS Immunol Med Mic 39: 279-286.
22. Higano CS, Schellhammer PF, Small EJ, Burch PA, Nemunaitis J, Yuh L, Provost N & Frohlich MW (2009) Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer. Cancer 115: 3670-3679.
23. Higgins JP, Bernstein MB & Hodge JW (2009) Enhancing immune responses to tumor-associated antigens. Cancer Biol Ther 8: 1440-1449.
24. Hodge JW, Guha C, Neefjes J & Gulley JL (2008) Synergizing radiation therapy and immunotherapy for curing incurable cancers. Opportunities and challenges. Oncology (Williston Park) 22: 1064-1070; discussion 1075, 1080-1061, 1084.
25. Horio Y, Chen A, Rice P, Roth JA, Malkinson AM & Schrump DS (1996) Ki-ras and p53 mutations are early and late events, respectively, in urethane-induced pulmonary carcinogenesis in A/J mice. Mol Carcinogen 17: 217-223.
26. Huang EH & Kaufman HL (2002) CEA-based vaccines. Expert Rev Vaccines 1: 49-63.
27. Kamrava M, Bernstein MB, Camphausen K & Hodge JW (2009) Combining radiation, immunotherapy, and antiangiogenesis agents in the management of cancer: the three musketeers or just another quixotic combination? Mol Biosyst 5: 1262-1270.
28. Kantoff PW, Schuetz TJ, Blumenstein BA et al. (2010) Overall survival analysis of a phase II randomized controlled trial of a poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer. J Clin Oncol 28: 1099-1105.
29. Lake RA & Robinson BW (2005) Immunotherapy and chemotherapy - a practical partnership. Nat Rev Cancer 5: 397-405.
30. Levitt ML, Kassem B, Gooding WE et al. (2004) Phase I study of gemcitabine given weekly as a short infusion for non-small cell lung cancer: results and possible immune system-related mechanisms. Lung Cancer 43: 335-344.
31. Lu Y, Bellgrau D, Dwyer-Nield LD, Malkinson AM, Duke RC, Rodell TC & Franzusoff A (2004) Mutation-selective tumor remission with Ras-targeted, whole yeast-based immunotherapy. Cancer Res 64: 5084-5088.
32. McAleer WJ, Buynak EB, Maigetter RZ, Wampler DE, Miller WJ & Hilleman MR (1984) Human hepatitis B vaccine from recombinant yeast. Nature 307: 178-180.
33. McHutchison JG, Jacobson IM, Boyer TD et al. (2009) GI-5005 therapeutic vaccine plus peg-IFN/ribavirin improves end of treatment response at 48 weeks versus peg-IFN/ribavirin in naïve genotype 1 chronic HCV patients [abstract]. Hepatology 50 (Suppl S4): 228A.
34. Munson S, Parker J, King TH, Lu Y, Kelley V, Guo Z, Borges V & Franzusoff A (2008) Coupling innate and adaptive immunity with yeast-based cancer immunotherapy. Cancer Vaccines and Tumor Immunity (Orentas R, Hodge JW & Johnson BD, eds), pp. 131-149. John Wiley & Sons, Hoboken, NJ.
35. Nowak AK, Lake RA, Marzo AL, Scott B, Heath WR, Collins EJ, Frelinger JA & Robinson BW (2003a) Induction of tumor cell apoptosis in vivo increases tumor antigen cross-presentation, cross-priming rather than cross-tolerizing host tumor-specific CD8 T cells. J Immunol 170: 4905-4913.
36. Nowak AK, Robinson BW & Lake RA (2003b) Synergy between chemotherapy and immunotherapy in the treatment of established murine solid tumors. Cancer Res 63: 4490-4496.
37. Plate JM, Plate AE, Shott S, Bograd S & Harris JE (2005) Effect of gemcitabine on immune cells in subjects with adenocarcinoma of the pancreas. Cancer Immunol Immun 54: 915-925.
38. Rehermann B & Nascimbeni M (2005) Immunology of hepatitis B virus and hepatitis C virus infection. Nat Rev Immunol 5: 215-229.
39. Reits EA, Hodge JW, Herberts CA et al. (2006) Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy. J Exp Med 203: 1259-1271.
40. Remondo C, Cereda V, Mostbock S, Sabzevari H, Franzusoff A, Schlom J & Tsang K-Y (2009) Human dendritic cell maturation and activation by a heat-killed recombinant yeast (Saccharomyces cerevisiae) vector encoding carcinoembryonic antigen. Vaccine 27: 987-994.
41. Riemann H, Takao J, Shellman YG, Hines WA, Edwards CK III, Franzusoff A, Norris DA & Fujita M (2007) Generation of a prophylactic melanoma vaccine using whole recombinant yeast expressing MART-1. Exp Dermatol 16: 814-822.
42. Schiff ER, Everson GT, Tsai N et al. (2007) HCV-specific cellular immunity, RNA reductions, and normalization of ALT in chronic HCV subjects after treatment with GI-5005, a yeast-based immunotherapy targeting NS3 and core: a randomized, double-blind, placebo controlled phase 1b study [abstract 1304]. Hepatology 46 (Suppl S1): 816A.
43. Schiller JT, Castellsague X, Villa LL & Hildesheim A (2008) An update of prophylactic human papillomavirus L1 virus-like particle vaccine clinical trial results. Vaccine 26 (suppl 10): K53-K61.
44. Schlom J, Arlen PM & Gulley JL (2007) Cancer vaccines: moving beyond current paradigms. Clin Cancer Res 13: 3776-3782.
45. Stanley M (2008) Immunobiology of HPV and HPV vaccines. Gynecol Oncol 109: S15-S21.
46. Stenger S, Hanson DA, Teitelbaum R et al. (1998) An antimicrobial activity of cytolytic T cells mediated by granulysin. Science 282: 121-125.
47. Stubbs AC & Wilson CC (2002) Recombinant yeast as a vaccine vector for the induction of cytotoxic T-lymphocyte responses. Curr Opin Mol Ther 4: 35-40.
48. Stubbs AC, Martin KS, Coeshott C, Skaates SV, Kuritzkes DR, Bellgrau D, Franzusoff A, Duke RC & Wilson CC (2001) Whole recombinant yeast vaccine activates dendritic cells and elicits protective cell-mediated immunity. Nat Med 7: 625-629.
49. Wansley EK, Chakraborty M, Hance KW et al. (2008) Vaccination with a recombinant Saccharomyces cerevisiae expressing a tumor antigen breaks immune tolerance and elicits therapeutic antitumor responses. Clin Cancer Res 14: 4316-4325.
50. Zitvogel L, Apetoh L, Ghiringhelli F & Kroemer G (2008) Immunological aspects of cancer chemotherapy. Nat Rev Immunol 8: 59-73.